Sie sind hier: Skip Navigation LinksKlinik und Poliklinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie und Infektiologie

Publikationen des Forschungslabors Hepatologie

Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, et al. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP reports : innovation in hepatology 2020;2:100169; PMID:32835190; https://doi.org/10.1016/j.jhepr.2020.100169.

Lampertico P, Berg T, Buti M, Pathil A, Petersen J, Ryder SD, et al. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. Alimentary pharmacology & therapeutics 2020;52:500–512; PMID:32583915; https://doi.org/10.1111/apt.15901.

Newsome PN, Berg T. 2020 - A new decade of innovation for EASL. Journal of hepatology 2020;72:8; PMID:31849349; https://doi.org/10.1016/j.jhep.2019.10.016.

Spormann L, Rennert C, Kolbe E, Ott F, Lossius C, Lehmann R, et al. Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver. Cells 2020;9; PMID:32751882; https://doi.org/10.3390/cells9081817.

Stickel F, Lutz P, Buch S, Nischalke HD, Silva I, Rausch V, et al. Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. Hepatology (Baltimore, Md.) 2020;72:88–102; PMID:31630428; https://doi.org/10.1002/hep.30996.

Tacke F, Boeker KHW, Klinker H, Heyne R, Buggisch P, Pathil A, et al. Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. Liver international : official journal of the International Association for the Study of the Liver 2020;40:539–548; PMID:31241820; https://doi.org/10.1111/liv.14186.

Thangapandi VR, Knittelfelder O, Brosch M, Patsenker E, Vvedenskaya O, Buch S, et al. Loss of hepatic Mboat7 leads to liver fibrosis. Gut 2020; PMID:32591434; https://doi.org/10.1136/gutjnl-2020-320853.

Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, et al. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of hepatology 2020; PMID:32673741; https://doi.org/10.1016/j.jhep.2020.06.013.

Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology 2019;156:431–445; PMID:30342035; https://doi.org/10.1053/j.gastro.2018.10.024.

Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. Alimentary pharmacology & therapeutics 2019;49:1052–1059; PMID:30874328; https://doi.org/10.1111/apt.15222.

Dietz J, Spengler U, Müllhaupt B, zur Schulze Wiesch J, Piecha F, Mauss S, et al. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2019; PMID:31706062; https://doi.org/10.1016/j.cgh.2019.10.051.

Efe C, Taşçilar K, Henriksson I, Lytvyak E, Alalkim F, Trivedi H, et al. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis. The American journal of gastroenterology 2019;114:1101–1108; PMID:31241547; https://doi.org/10.14309/ajg.0000000000000290.

Gerhardt F, Benesic A, Tillmann HL, Rademacher S, Wittekind C, Gerbes AL, et al. Iberogast-Induced Acute Liver Failure-Reexposure and In Vitro Assay Support Causality. The American journal of gastroenterology 2019;114:1358–1359; PMID:31246695; https://doi.org/10.14309/ajg.0000000000000300.

Gerhardt F, Maier M, Liebert UG, Platzbecker U, Wang S-Y, Papp CP, et al. Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing. Antimicrobial agents and chemotherapy 2019;64; PMID:31685465; https://doi.org/10.1128/AAC.01525-19.

Jalan R, Bataller R, Berg T, Lotersztajn S, Moreau R, Zucman-Rossi J, et al. Journal of Hepatology: The Home of Liver Research, 2015-2019. Journal of hepatology 2019;71:1065–1069; PMID:31739918; https://doi.org/10.1016/j.jhep.2019.09.017.

Koukoulioti E, Brodzinski A, Mihm U, Sarrazin C, Jung M-C, Schott E, et al. Risk factors for resistance development against lamivudine during long-term treatment of chronic hepatitis B virus infections. European journal of gastroenterology & hepatology 2019;31:845–852; PMID:30789375; https://doi.org/10.1097/MEG.0000000000001351.

Metwally M, Bayoumi A, Romero-Gomez M, Thabet K, John M, Adams LA, et al. A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3'UTR. Journal of hepatology 2019;70:494–500; PMID:30389552; https://doi.org/10.1016/j.jhep.2018.10.021.

Olbrich A, Wardemann H, Böhm S, Rother K, Colpitts CC, Wrensch F, et al. Repertoire and Neutralizing Activity of Antibodies Against Hepatitis C Virus E2 Peptide in Patients With Spontaneous Resolution of Hepatitis C. The Journal of infectious diseases 2019;220:1209–1218; PMID:31165162; https://doi.org/10.1093/infdis/jiz274.

Strnad P, Buch S, Hamesch K, Fischer J, Rosendahl J, Schmelz R, et al. Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. Gut 2019;68:1099–1107; PMID:30068662; https://doi.org/10.1136/gutjnl-2018-316228.

Sucher E, Sucher R, Gradistanac T, Brandacher G, Schneeberger S, Berg T. Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies. Journal of immunology research 2019;2019:9437043; PMID:31886312; https://doi.org/10.1155/2019/9437043.

Wiltberger G, Wu Y, Lange U, Hau H-M, Tapper E, Krenzien F, et al. Protective effects of coffee consumption following liver transplantation for hepatocellular carcinoma in cirrhosis. Alimentary pharmacology & therapeutics 2019;49:779–788; PMID:30811647; https://doi.org/10.1111/apt.15089.

El Sharkawy R, Thabet K, Lampertico P, Petta S, Mangia A, Berg T, et al. A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. Alimentary pharmacology & therapeutics 2018;48:564–573; PMID:29963713; https://doi.org/10.1111/apt.14866.

Engelmann C, Schob S, Nonnenmacher I, Werlich L, Aehling N, Ullrich S, et al. Loss of paraspinal muscle mass is a gender-specific consequence of cirrhosis that predicts complications and death. Alimentary pharmacology & therapeutics 2018;48:1271–1281; PMID:30417398; https://doi.org/10.1111/apt.15026.

van Bömmel F, van Bömmel A, Krauel A, Wat C, Pavlovic V, Yang L, et al. Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B. The Journal of infectious diseases 2018;218:1066–1074; PMID:29741634; https://doi.org/10.1093/infdis/jiy270.

van Campenhout MJH, van Bömmel F, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, et al. Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. Hepatology (Baltimore, Md.) 2018;68:839–847; PMID:29514389; https://doi.org/10.1002/hep.29872.

Stickel F, Buch S, Nischalke HD, Weiss KH, Gotthardt D, Fischer J, et al. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis. The American journal of gastroenterology 2018;113:1475–1483; PMID:29535416; https://doi.org/10.1038/s41395-018-0041-8.

Papatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, van Boemmel F, Buti M, et al. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. Journal of hepatology 2018;68:1129–1136; PMID:29427727; https://doi.org/10.1016/j.jhep.2018.01.031.

Pfefferkorn M, Böhm S, Schott T, Deichsel D, Bremer CM, Schröder K, et al. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers. Gut 2018;67:2045–2053; PMID:28951526; https://doi.org/10.1136/gutjnl-2017-313811.

Herzer K, Gerken G, Kroy D, Tacke F, Plewe J, Eurich D, et al. Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. Journal of hepatology 2018;69:982–984; PMID:30089577; https://doi.org/10.1016/j.jhep.2018.07.001.​

Liebigstraße 20 und 22, Haus 4 und 7
04103 Leipzig
Telefon:
0341 - 97 12200
Map